Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 345

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 345
---
 make discretionary profit sharing and 401(k) matching contributions as defined in the plan and as approved by the Board of Directors. The Company’s contributions for the period from February 14, 2024 through March 31, 2024 was $ 7,956and Predecessor contributions during the period from January 1, 2024 through February 13, 2024 was $ 4,685. The Company did not make any contributions to the 401(k) during the three months ended March 31, 2025.

NOTE 13 – RELATED-PARTY TRANSACTIONS

In February 2024, we issued
and sold an aggregate of shares of Series A Preferred Stock, Series A Common Warrants and Preferred Warrants, at a
price of $ per share of Series A Preferred Stock, for aggregate cash proceeds of approximately $ million, plus additional cash proceeds
of up to $ million if the Preferred Warrants are exercised.

The following table summarizes
the shares of our Series A Preferred Stock issued to our related parties:

| Purchasers                              |     | Shares of          
 Series A Preferred 
 Stock              |       |     | Total    
 Purchase 
 Price    |           |
|:----------------------------------------|:----|:-------------------|------:|:----|:---------|----------:|
| Daniel Corey(1)                         |     |                    |   150 |     | $        |   150,000 |
| Atwood-Edminster Trust dtd 4-2-2000 (2) |     |                    | 1,002 |     | $        | 1,002,000 |
| Chris Ehrlich(3)                        |     |                    |   275 |     | $        |   275,000 |

F-29

On February 5, 2025, the
Company announced the pricing of a reasonable best efforts public offering (the “Offering”), with participation from a member
of the Company’s board of directors and a single institutional investor, for the purchase and sale of (i) 300,00 shares of common
stock, (ii) February 2025 Pre-funded Warrants; and (iii) common warrants to purchase up to shares of common stock
(the “February 2025 Common Warrants”), at a combined public offering price of $ per share and Warrant (See Note 8).

The following table summarizes
the pre-funded warrants and February 2025 Common Warrants sold to our related